%20-%20http://www.bohemiancoding.com/sketch%20--%3e%3ctitle%3eIcon/Menu%3c/title%3e%3cdesc%3eCreated%20with%20Sketch.%3c/desc%3e%3cdefs%3e%3cpolygon%20id='path-1'%20points='0.0005%200.646%2022.386%200.646%2022.386%203.1455%200.0005%203.1455'%3e%3c/polygon%3e%3cpolygon%20id='path-3'%20points='0.0005%200.9341%2022.386%200.9341%2022.386%203.4341%200.0005%203.4341'%3e%3c/polygon%3e%3cpolygon%20id='path-5'%20points='0.0005%200.5%2022.386%200.5%2022.386%203%200.0005%203'%3e%3c/polygon%3e%3c/defs%3e%3cg%20id='Symbols'%20stroke='none'%20stroke-width='1'%20fill='none'%20fill-rule='evenodd'%3e%3cg%20id='Icon/Menu'%3e%3cg%20id='Group-10-Copy'%20transform='translate(3.800000,%205.300000)'%3e%3cg%20id='Group-3'%20transform='translate(0.000000,%200.354500)'%3e%3cmask%20id='mask-2'%20fill='white'%3e%3cuse%20xlink:href='%23path-1'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-2'%3e%3c/g%3e%3cpath%20d='M22.3865,2.6455%20C22.3865,2.9205%2022.1615,3.1455%2021.8865,3.1455%20L0.5005,3.1455%20C0.2245,3.1455%200.0005,2.9205%200.0005,2.6455%20L0.0005,1.1455%20C0.0005,0.8705%200.2245,0.6455%200.5005,0.6455%20L21.8865,0.6455%20C22.1615,0.6455%2022.3865,0.8705%2022.3865,1.1455%20L22.3865,2.6455%20Z'%20id='Fill-1'%20fill='%23FFFFFF'%20mask='url(%23mask-2)'%3e%3c/path%3e%3c/g%3e%3cg%20id='Group-6'%20transform='translate(0.000000,%207.354500)'%3e%3cmask%20id='mask-4'%20fill='white'%3e%3cuse%20xlink:href='%23path-3'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-5'%3e%3c/g%3e%3cpath%20d='M22.3865,2.9341%20C22.3865,3.2091%2022.1615,3.4341%2021.8865,3.4341%20L0.5005,3.4341%20C0.2245,3.4341%200.0005,3.2091%200.0005,2.9341%20L0.0005,1.4341%20C0.0005,1.1591%200.2245,0.9341%200.5005,0.9341%20L21.8865,0.9341%20C22.1615,0.9341%2022.3865,1.1591%2022.3865,1.4341%20L22.3865,2.9341%20Z'%20id='Fill-4'%20fill='%23FFFFFF'%20mask='url(%23mask-4)'%3e%3c/path%3e%3c/g%3e%3cg%20id='Group-9'%20transform='translate(0.000000,%2015.354500)'%3e%3cmask%20id='mask-6'%20fill='white'%3e%3cuse%20xlink:href='%23path-5'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-8'%3e%3c/g%3e%3cpath%20d='M22.3865,2.5%20C22.3865,2.775%2022.1615,3%2021.8865,3%20L0.5005,3%20C0.2245,3%200.0005,2.775%200.0005,2.5%20L0.0005,1%20C0.0005,0.725%200.2245,0.5%200.5005,0.5%20L21.8865,0.5%20C22.1615,0.5%2022.3865,0.725%2022.3865,1%20L22.3865,2.5%20Z'%20id='Fill-7'%20fill='%23FFFFFF'%20mask='url(%23mask-6)'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23fff'%20fill-rule='nonzero'%3e%3cg%20id='icon/fold'%20transform='translate(240.000000,%20272.000000)'%3e%3cpath%20d='M11.5,2.3%20C6.4216,2.3%202.3,6.4216%202.3,11.5%20C2.3,16.5784%206.4216,20.7%2011.5,20.7%20C16.5784,20.7%2020.7,16.5784%2020.7,11.5%20C20.7,6.4216%2016.5784,2.3%2011.5,2.3%20Z%20M10.58,18.7956%20C6.946,18.3448%204.14,15.2536%204.14,11.5%20C4.14,10.9296%204.2136,10.3868%204.3332,9.8532%20L8.74,14.26%20L8.74,15.18%20C8.74,16.192%209.568,17.02%2010.58,17.02%20L10.58,18.7956%20Z%20M16.928,16.4588%20C16.6888,15.7136%2016.008,15.18%2015.18,15.18%20L14.26,15.18%20L14.26,12.42%20C14.26,11.914%2013.846,11.5%2013.34,11.5%20L7.82,11.5%20L7.82,9.66%20L9.66,9.66%20C10.166,9.66%2010.58,9.246%2010.58,8.74%20L10.58,6.9%20L12.42,6.9%20C13.432,6.9%2014.26,6.072%2014.26,5.06%20L14.26,4.6828%20C16.9556,5.7776%2018.86,8.418%2018.86,11.5%20C18.86,13.4136%2018.124,15.1524%2016.928,16.4588%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
WuXi AppTec News & Press Releases - Latest Pharmaceutical Industry Updates
News
Press Releases
2018/06/14
WuXi STA First CDMO to Support the Approval of an Innovative Drug in China Through the “MAH” Pilot
SHANGHAI, June 14, 2018: STA Pharmaceutical Co., Ltd. (WuXi STA), a subsidiary of WuXi AppTec, congratulates its partner Ascletis for receiving approval from National Drug Administration of China (CNDA, former CFDA) of its Category 1 new drug, Ganovo® (also known as Danoprevir or ASC08), to treat viral hepatitis C.
Read more2018/05/08
WuXi AppTec Announces Listing of Initial Public Offering of Common Stock on Shanghai Stock Exchange
SHANGHAI, May 8, 2018--- WuXi AppTec Co., Ltd. (“WuXi AppTec” or “the Company”; Stock Code: 603259), a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced listing of its initial public offering of 104,198,600 shares of common stock at a public offering price of RMB21.60 per share. Proceeds from the IPO will be used to build and expand its R&D facilities in China, further strengthening its capabilities and capacities to better serve global customers and partners.
Read more2018/05/07
WuXi STA Changzhou Site Passes First U.S. FDA Inspection
SHANGHAI, May 7, 2018: STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, announces that its active pharmaceutical ingredient (API) R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection (PAI) for two APIs from the U.S. Food and Drug Administration (FDA) – with no Form 483s issued. This is the first time that WuXi STA’s Changzhou facility has been inspected by the FDA.
Read more2018/04/19
WuXi AppTec Expands Site in the United States for Drug Development Testing Services
SHANGHAI and CRANBURY,NJ, April 19, 2018 – WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced the opening of its expanded Laboratory Testing Division (LTD) facility in New Jersey. The grand opening event was honored by the presence of state and local officials including State Senator Linda Greenstein. The new facility will enhance WuXi’s integrated testing service portfolio enabling drug developers to accelerate their projects from labs to patients.
Read more2018/02/22
WuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration
Shanghai, February 22, 2018 - STA Pharmaceutical Co., Ltd. (STA), a WuXi AppTec company and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing, and Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announce they have entered into an oligonucleotide synthesis collaboration agreement for research and mid-scale non-GMP/cGMP manufacturing.
Read more